Journals / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 8

Evaluation of post-transplant complications, patientand graft survival in patients with autosomal dominantpolycystic kidney disease after renal transplantation;A single center experience

Pages
1450–1456
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients with ADPKD after transplantation may have a higher incidence of ischemic heart disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AbstractAim: Autosomal dominant polycystic kidney disease (ADPKD) is systemic, progressive hereditary disease, characterized by cyst formation in multiple organs.
📊
Key Findings & Data:We included 28 patients in ADPKD and 28 patients in the control group.
💡
Conclusion & Impact:Patients with ADPKD after transplantation may have a higher incidence of ischemic heart disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

AbstractAim: Autosomal dominant polycystic kidney disease (ADPKD) is systemic, progressive hereditary disease, characterized by cyst formation in multiple organs. Patients with ADPKD mostly develop end stage renal disease (ESRD) and require renal replacement therapy, preferably renal transplantation (RT). In this study, we aimed to compare the post-RT complications, patient and graft survivals in patients with ADPKD and other etiologies of ESRD. Materials and Methods: We retrospectively evaluated patients’ baseline characteristics, post-RT complications, patient and graft survival in patients with ESRD underwent renal transplantation due to ADPKD and other etiologies. We included 28 patients in ADPKD and 28 patients in the control group. Results: The mean survival time was 224.83 ± 7.53 months in all patients. During follow-up period 1 patient died in both groups and 10 years patients and graft survivals were similar for both groups. The graft survival, acute and chronic rejections and glomerular filtration rate levels were similar in both groups end of the first year of RT but total cholesterol and glucose levels were significantly higher in the ADPKD group. Moreover, developing of ischemic heart disease was significantly higher in ADPKD (32% vs 0%, p=0.002), the other complication rates were similar in both. Conclusion: As a comparesion to patients with ESRD underwent RT due to ADPKD and different etiologies, both groups have similar patient and graft survival rates. Patients with ADPKD after transplantation may have a higher incidence of ischemic heart disease.

🔖

Cite This Article

ÖKSÜZ, E., BUĞDAY, M. S., BUĞDAY, Ç., TÜRKMEN, A. (2022). Evaluation of post-transplant complications, patientand graft survival in patients with autosomal dominantpolycystic kidney disease after renal transplantation;A single center experience. Annals of Medical Research, Cilt: 28 - Sayı: 8, 1450–1456. https://ajindex.com/articles/445699

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Torres VE, Harris PC., Pirson, Y. Autosomal dominant polycystic kidney disease. Lancet 2007;369:1287- 301
  2. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2009;60:321-37
  3. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005;45:5-7, S1-S280
  4. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993;329:332
  5. Shaw C, Simms RJ, Pitcher D, et al. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure. Nephrol Dial Transplant 2014;29:1910– 8
  6. Pirson, Y. Extrarenal manifestations of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010;17:173-80
  7. Luciano RL, Dahl NK. Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management. Nephrol. Dial. Transplant 2014;29:247- 54
  8. Torra R, Sarquella J, Calabia J,et al. Prevalence of cysts in seminal tract and abnormal semen parameters in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2008;3:790-3
  9. Kumar S, Adeva M, King BF, et al. Duodenal diverticulosis in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2006;21:3576-8. 10. 1Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009;76:149
  10. Spithoven EM, Kramer A, Meijer E, et al. Renal replacement therapy for ADPKD in Europe: prevalence and survival. An analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2014;29:15-25
  11. Schnuelle P, Lorenz D, Trede M, et al. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term followup. J Am Soc Nephrol 1998;9:2135
  12. Hadimeri H, Norden G, Friman S, et al. Autosomal dominant polycystic kidney disease in a kidney transplant population. Nephrol Dial Transplant.1997;12:1431-6
  13. Fitzpatrick PM, Torres VE, Charboneau JW, et al. Longterm outcome of renal transplantation in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1990;15:535-43
  14. Florijn KW, Chang PC, van der Woude FJ, et al. Long-term cardiovascular morbidity and mortality in autosomal dominant polycystic kidney disease patients after renal transplantation. Transplantation 1994;57:7